The IL4 Knockout 786-O Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 786-O renal cell carcinoma cell line. This product enables loss-of-function studies of the IL4 gene, which encodes the interleukin-4 cytokine. The polyclonal knockout model provides a genetically heterogeneous pool of cells with targeted disruption of IL4, generated via CRISPR/Cas9-mediated gene perturbation. These cells are intended for advanced research applications investigating IL-4-dependent signaling pathways and functional roles in tumor biology and immune modulation.
786-O is an established clear cell renal cell carcinoma line characterized by a VHL tumor suppressor gene mutation, leading to constitutive activation of hypoxia-inducible factor (HIF) pathways. This line is widely used to model human renal cell carcinoma, particularly the clear cell subtype, and exhibits malignant epithelial properties. The VHL mutation context makes these cells valuable for studying tumor microenvironment interactions and hypoxia-driven cancer phenotypes. The knockout of IL4 in this background allows dissection of cytokine-mediated immunoregulatory events in a genetically defined cancer setting.
IL-4 is a pleiotropic cytokine central to Th2 immune responses. The mechanistic pathway involves binding to the IL-4 receptor complex, composed of IL4RA and the common gamma chain (IL2RG), which activates JAK1 and JAK3 kinases. This triggers phosphorylation and dimerization of STAT6, a downstream transcription factor. Phosphorylated STAT6 translocates to the nucleus and promotes expression of Th2-associated genes such as GATA3 and initiates IgE germline transcription via FCER2 (CD23) regulation. Upstream regulators of IL-4 expression include transcription factors GATA3, NFAT, c-Maf, and AP-1, often in response to IL-2 and CD28 co-stimulation. Negative feedback is mediated by SOCS1. The pathway also intersects with PI3K-AKT signaling. Thus, IL-4 acts as a master regulator of humoral immunity and Th2 differentiation.
In the context of renal cell carcinoma, IL-4 signaling may contribute to tumor immune evasion by shaping the tumor microenvironment and influencing T cell differentiation. The 786-O cell line, with its VHL mutation and clear cell phenotype, provides a relevant model to explore how IL-4 modulates interactions between tumor cells and immune components. Disruption of IL4 in this background allows investigation of cytokine-dependent mechanisms that may affect tumor progression, immune cell recruitment, and response to immunotherapies. This model is particularly suited to dissect the role of Th2 cytokines in cancer, where they are often associated with immunosuppressive networks.
Researchers can employ this polyclonal knockout cell population in diverse experimental workflows. Representative assays include western blotting to assess STAT6 phosphorylation, RT-qPCR for IL-4 and downstream gene expression, ELISA to quantify IL-4 secretion, and flow cytometry for surface marker analysis. Co-culture experiments with immune cells can be conducted to study tumor-immune interactions, and RNA-seq can provide transcriptomic insights into IL-4-dependent programs. These applications support studies in cancer immunobiology, T cell differentiation, allergic disease mechanisms, and therapeutic target evaluation. For further information or customized services, please contact Ascent Research.
